<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02145208</url>
  </required_header>
  <id_info>
    <org_study_id>MT-02</org_study_id>
    <nct_id>NCT02145208</nct_id>
  </id_info>
  <brief_title>Study to Assess the Efficacy of Medi-Tate iTind Device</brief_title>
  <official_title>One-arm, Multi-center, International Prospective Study to Assess the Efficacy of Medi-Tate Temporary Implantable Nitinol Device (iTindTM) in Subjects With Benign Prostatic Hypertrophy (BPH).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medi-Tate Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medi-Tate Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will include an implantation of the iTind device and 4 follow up visits up to 12&#xD;
      months after the implantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After screening , eligible patients will undergo an an implantation procedure (operative),&#xD;
      using the iTind device.&#xD;
&#xD;
      Implantation will be performed according to the Instructions For Use.&#xD;
&#xD;
      Between the 5th - 7th days, the iTind will be retrieved through a rigid cystoscope sheath,&#xD;
      under direct vision. Before retrieval the subject will be asked for subjective discomfort&#xD;
      evaluation and level of urgency in the past days after device insertion, about any AE and&#xD;
      then the device will be retrieved.&#xD;
&#xD;
      The next visits will be at 4 weeks (post device retrieval), 3 months, 6 months, and 12 months&#xD;
      post implantation with an optional extension of follow up period (up to 36 months). In the&#xD;
      visits the following will be assessed: Uroflow and residual urine volume tests, AE recording,&#xD;
      IPSS, and Questions on sex performing capability and ejaculation filled out by the subjects,&#xD;
      in the local languages.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 2014</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>iTind</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of IPSS score by at least 3 points, in at least 75 % of the subjects, at 6 months follow-up.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The incidence of unexpected serious adverse events related to Meditate iTind and/or implantation/retrieval procedures, as determined by the investigator and the study medical monitor.</measure>
    <time_frame>5-7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Increase of maximal urinary peak flow</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Benign Prostatic Hyperplasia (BPH)</condition>
  <arm_group>
    <arm_group_label>Medi-Tate iTind</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TIND System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TIND System</intervention_name>
    <description>An implant</description>
    <arm_group_label>Medi-Tate iTind</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject signed informed consent prior to the performance of any study procedures.&#xD;
&#xD;
          -  Male with symptomatic BPH. IPSS symptom severity score above 10. Peak urinary flow of&#xD;
             below 12 ml/sec&#xD;
&#xD;
          -  Prostate volume below 75 ml&#xD;
&#xD;
          -  Blood CBC and biochemistry up to two weeks before screening demonstrating: Normal&#xD;
             values of the PT, PTT and INR tests (anticoagulants should be stopped according to&#xD;
             GCP)&#xD;
&#xD;
          -  Subject that able to complete the study protocol.&#xD;
&#xD;
          -  Normal Urinalysis and urine culture&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  cardiac arrhythmias, cardiac disease including congestive heart failure, uncontrolled&#xD;
             diabetes mellitus, significant respiratory disease, or known immunosuppression;&#xD;
&#xD;
          -  neurogenic bladder and/or sphincter abnormalities due to Parkinson's disease, multiple&#xD;
             sclerosis, cerebral vascular accident, diabetes, etc.;&#xD;
&#xD;
          -  a post void residual (PVR) volume above 250 ml measured by ultrasound or acute urinary&#xD;
             retention&#xD;
&#xD;
          -  compromised renal function (i.e., serum creatinine level above 1.8 mg/dl, or upper&#xD;
             tract disease);&#xD;
&#xD;
          -  confirmed or suspected bladder cancer;&#xD;
&#xD;
          -  recent (within 3 months) cystolithiasis or hematuria;&#xD;
&#xD;
          -  urethral strictures, bladder neck contracture, Urinary bladder stones&#xD;
&#xD;
          -  or other potentially confounding bladder pathology;&#xD;
&#xD;
          -  an active urinary tract infection.&#xD;
&#xD;
          -  Enrolled in another treatment trial for any disease within the past 30 days.&#xD;
&#xD;
          -  previous rectal surgery (other than hemorrhoidectomy) or history of rectal disease if&#xD;
             the therapy may potentially cause injury to sites of previous rectal surgery, e.g., if&#xD;
             a transrectal probe is used;&#xD;
&#xD;
          -  previous pelvic irradiation or radical pelvic surgery;&#xD;
&#xD;
          -  previous prostate surgery, balloon dilatation, stent implantation, laser&#xD;
             prostatectomy, hyperthermia, or any other invasive treatment to the prostate&#xD;
&#xD;
          -  Cancer that is not considered cured, except basal cell or squamous cell carcinoma of&#xD;
             the skin (cured defined as no evidence of cancer within the past 5 years).&#xD;
&#xD;
          -  Subject has an interest in future fertility and is not willing to undergo fertility&#xD;
             treatments whatsoever.&#xD;
&#xD;
          -  Any serious medical condition likely to impede successful completion of the study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claude Schulman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Edith cavell clinic, Belgium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Edith Cavell</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gent Hospital University</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Orbessano</name>
      <address>
        <city>Turin</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>La Paz Hospital</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Frauenfeld</name>
      <address>
        <city>Frauenfeld</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lausanne University Hospital</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frimley Health NHS</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
    <country>Germany</country>
  </removed_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 20, 2014</study_first_submitted>
  <study_first_submitted_qc>May 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2014</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BPH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

